UV Raman Spectroscopy for Medical Detection: inside the UV4LIFE project

UV Raman spectroscopy is emerging as one of the most promising approaches for fast, minimally invasive medical diagnostics: detecting infections, tumors, and metabolic disorders with greater selectivity than near-infrared excitation. The UV4LIFE collaborative R&D project, funded by Région Bretagne, Lannion-Trégor Communauté and the European FEDER fund, pushes Raman excitation wavelengths into the near-UV range and develops the compact solid-state laser sources needed to make this technology viable for both laboratory and future medical instrument integration.

Why UV Raman Spectroscopy Outperforms Near-Infrared for Medical Diagnostics

Medicine is increasingly seeking fast and minimally invasive diagnostic methods, particularly for infections, tumor-related diseases, and metabolic disorders. Raman spectroscopy, recently tested on these conditions, shows strong potential. Experiments conducted in INSERM laboratories indicate that excitation wavelengths in the visible range perform better than those in the near-infrared.

UV Raman spectroscopy takes this further by pushing excitation into the near-UV range, where molecular signatures are sharper and fluorescence background interference — a major limitation of visible and near-infrared Raman — is significantly reduced. This translates into improved selectivity and sensitivity when analyzing complex biological samples such as cancer cells or bacterial cultures, making UV Raman a compelling candidate for next-generation clinical diagnostic tools.

The components and UV Raman spectrometer developed in this project also have many additional potential applications, including 2D materials analysis for batteries, ink characterization, excitation of UV fluorophores for cytometry and microscopy.

3 Objectives: Solid-State UV Lasers, UV Raman Spectroscopy and Cancer Cell Analysis

Today, Raman spectrometers have become more compact and stable thanks to the replacement of gas lasers with solid-state lasers (at 532 nm, 640 nm, and 785 nm). However, the fourth most commonly used wavelength (325 nm in the near-UV) is still provided by a Helium-Cadmium (HeCd) gas laser, 200 times larger and 20 times more energy-consuming than solid-state lasers. This limits laboratory use and makes future medical instrument integration impossible.

The UV4LIFE project addresses this bottleneck through three sequential objectives:

The first is to develop compact solid-state UV laser sources: one at 320 nm as a direct replacement for HeCd lasers, and another at 375 nm based on diode technology.
The second objective is to integrate these new sources into a UV Raman spectrometer, enabling medical researchers to exploit these wavelengths for biological sample analysis.
The third objective is to apply this new tool to the analysis of cancer cells and bacteria, and to derive robust detection and identification processes from the results.

Oxxius Contribution: 320 nm Single-Frequency UV Laser for Raman Spectroscopy

Oxxius leads the UV4LIFE project and takes direct responsibility for the most technically demanding deliverable: the development of a single-frequency solid-state laser at 320 nm — a wavelength with no commercially available solid-state equivalent at the project’s launch. This laser is designed to match the performance of HeCd sources in terms of spectral purity, while delivering the compactness, stability, and energy efficiency required for integration into medical-grade instrumentation. Oxxius also supports the adaptation of the UV Raman spectrometer for operation at these new wavelengths.

Funding

Oxxius’ participation in the UV4LIFE R&D project receives financial support from Région Bretagne, Lannion-Trégor Communauté and the European Union’s FEDER fund, reflecting the strategic importance of UV photonics innovation for both regional industrial development and European scientific competitiveness.

Project Partners

The UV4LIFE consortium brings together four complementary partners:

Institut Foton (SP/PLA Group – CNRS): responsible for spectral refinement of the 375 nm diode laser.
iXblue Photonics (now Exail): developing and manufacturing the Bragg gratings required for the project.
CIMIAD Team (UMR 1241, Numécan Institute – Inserm): in charge of UV Raman analysis on various biological samples.
Oxxius: developing the single-frequency 320 nm laser, supporting the adaptation of the UV Raman spectrometer and leading the overall project.